Brokerages Anticipate Xencor (XNCR) Will Post Quarterly Sales of $3.52 Million

Equities research analysts expect that Xencor (NASDAQ:XNCR) will report $3.52 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Xencor’s earnings, with estimates ranging from $560,000.00 to $5.00 million. Xencor posted sales of $4.34 million in the same quarter last year, which would indicate a negative year over year growth rate of 18.9%. The business is scheduled to report its next earnings results on Tuesday, May 8th.

On average, analysts expect that Xencor will report full year sales of $19.92 million for the current year, with estimates ranging from $19.76 million to $20.00 million. For the next financial year, analysts expect that the business will post sales of $19.49 million per share, with estimates ranging from $2.26 million to $28.70 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Xencor.

How to Become a New Pot Stock Millionaire

Xencor (NASDAQ:XNCR) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Xencor had a negative net margin of 137.35% and a negative return on equity of 16.62%. The firm had revenue of $10.94 million during the quarter, compared to analyst estimates of $15.65 million.



A number of analysts have commented on XNCR shares. Zacks Investment Research reaffirmed a “sell” rating on shares of Xencor in a report on Saturday, January 13th. BidaskClub raised shares of Xencor from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. Cantor Fitzgerald started coverage on shares of Xencor in a report on Thursday, February 22nd. They set a “buy” rating and a $33.00 target price for the company. Wedbush lifted their target price on shares of Xencor from $38.00 to $39.00 and gave the stock an “outperform” rating in a report on Monday, March 19th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $36.00 target price on shares of Xencor in a report on Wednesday, March 28th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $35.17.

XNCR traded down $0.73 during trading on Wednesday, reaching $29.15. 186,440 shares of the company’s stock were exchanged, compared to its average volume of 300,520. Xencor has a fifty-two week low of $18.55 and a fifty-two week high of $34.63. The firm has a market capitalization of $1,622.56, a PE ratio of -27.76 and a beta of 1.51.

In other news, insider Edgardo Baracchini, Jr. sold 40,000 shares of Xencor stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $30.89, for a total transaction of $1,235,600.00. Following the transaction, the insider now directly owns 40,000 shares of the company’s stock, valued at $1,235,600. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Paul A. Foster sold 5,000 shares of Xencor stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.01, for a total transaction of $125,050.00. Following the transaction, the insider now directly owns 7,419 shares in the company, valued at $185,549.19. The disclosure for this sale can be found here. Over the last three months, insiders have sold 105,000 shares of company stock worth $3,101,550. Insiders own 4.14% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Redmile Group LLC boosted its position in shares of Xencor by 12.5% during the fourth quarter. Redmile Group LLC now owns 1,350,894 shares of the biopharmaceutical company’s stock worth $29,612,000 after purchasing an additional 150,600 shares in the last quarter. Perceptive Advisors LLC boosted its position in shares of Xencor by 1.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,313,095 shares of the biopharmaceutical company’s stock worth $28,783,000 after purchasing an additional 20,000 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its position in shares of Xencor by 32.9% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 583,491 shares of the biopharmaceutical company’s stock worth $12,790,000 after purchasing an additional 144,319 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Xencor by 3.6% during the fourth quarter. Franklin Resources Inc. now owns 538,632 shares of the biopharmaceutical company’s stock worth $11,807,000 after purchasing an additional 18,900 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Xencor by 5.9% during the fourth quarter. Geode Capital Management LLC now owns 352,526 shares of the biopharmaceutical company’s stock worth $7,727,000 after purchasing an additional 19,706 shares in the last quarter. 68.79% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate Xencor (XNCR) Will Post Quarterly Sales of $3.52 Million” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://stocknewstimes.com/2018/04/23/brokerages-anticipate-xencor-xncr-will-post-quarterly-sales-of-3-52-million.html.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply